ARCHIVES

In Phase II Study, Vaccine IMA910 Stimulated Immune Response

This article is from The Cancer Letter archive.

Vol. 35 No. 2 | February 24, 2012

Download PDF Visit The Full Archive

Related Articles

ODAC Votes Against Adria’s Chemoprotector, Okays Leustatin

July 3, 1992

Two-Month Survival Benefit For Some NSCLC Patients

May 31, 2002

Conversation with The Cancer Letter: Daniel Hayes Leads Tour of Caris Website

August 8, 2014

ACS Probably Will Accept Hammer’s Offer On Matching Funds For Survey

February 3, 1984

NLST Shows 20.3 Percent Mortality Benefit For CT Vs. X-Ray In Lung Cancer Screening

November 5, 2010

NCCS Networker Volume 2 Issue 2, Spring 1988

April 13, 1988